表紙
市場調査レポート

神経線維腫症II型 (NF2):パイプライン製品の分析

Neurofibromatoses Type II - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 277753
出版日 ページ情報 英文 50 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
神経線維腫症II型 (NF2):パイプライン製品の分析 Neurofibromatoses Type II - Pipeline Review, H1 2016
出版日: 2016年04月27日 ページ情報: 英文 50 Pages
概要

神経線維腫症II型 (NF2) は、神経系の非癌性腫瘍の増殖を特徴とする疾患です。内耳から脳 (聴覚神経) へと情報を運ぶ神経に沿って発症します。他の神経で生じる腫瘍は、この状態で発見されることがよくあります。兆候と症状は、難聴、耳鳴り、平衡感覚の異常などがあります。

当レポートでは、神経線維腫症II型 (NF2) に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

神経線維腫症II型の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

神経線維腫症II型:企業で開発中の治療薬

神経線維腫症II型:大学/機関で研究中の治療薬

神経線維腫症II型:パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

神経線維腫症II型:企業で開発中の製品

神経線維腫症II型:大学/機関で研究中の製品

神経線維腫症II型の治療薬開発に従事している企業

  • Arno Therapeutics, Inc.
  • CalAsia Pharmaceuticals, Inc.
  • Lixte Biotechnology Holdings, Inc.
  • Novartis AG

神経線維腫症II型:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

神経線維腫症II型:最近のパイプライン動向

神経線維腫症II型:休止中のプロジェクト

神経線維腫症II型:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7921IDB

Summary

Global Markets Direct's, 'Neurofibromatoses Type II - Pipeline Review, H1 2016', provides an overview of the Neurofibromatoses Type II pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neurofibromatoses Type II, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neurofibromatoses Type II and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Neurofibromatoses Type II
  • The report reviews pipeline therapeutics for Neurofibromatoses Type II by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Neurofibromatoses Type II therapeutics and enlists all their major and minor projects
  • The report assesses Neurofibromatoses Type II therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Neurofibromatoses Type II

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Neurofibromatoses Type II
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Neurofibromatoses Type II pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Neurofibromatoses Type II Overview
  • Therapeutics Development
    • Pipeline Products for Neurofibromatoses Type II - Overview
    • Pipeline Products for Neurofibromatoses Type II - Comparative Analysis
  • Neurofibromatoses Type II - Therapeutics under Development by Companies
  • Neurofibromatoses Type II - Therapeutics under Investigation by Universities/Institutes
  • Neurofibromatoses Type II - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Neurofibromatoses Type II - Products under Development by Companies
  • Neurofibromatoses Type II - Products under Investigation by Universities/Institutes
  • Neurofibromatoses Type II - Companies Involved in Therapeutics Development
    • Arno Therapeutics, Inc.
    • CalAsia Pharmaceuticals, Inc.
    • Lixte Biotechnology Holdings, Inc.
    • Novartis AG
  • Neurofibromatoses Type II - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AR-42 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • everolimus - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FRAX-597 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LB-201 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LB-205 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Hsp90-Alpha and TRAP 1 for Neurofibromatosis Type 2 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Neurofibromatoses Type II - Recent Pipeline Updates
  • Neurofibromatoses Type II - Dormant Projects
  • Neurofibromatoses Type II - Product Development Milestones
    • Featured News & Press Releases
      • May 11, 2012: Arno Therapeutics Receives European Orphan Drug Designation For AR-42
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Neurofibromatoses Type II, H1 2016
  • Number of Products under Development for Neurofibromatoses Type II - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Neurofibromatoses Type II - Pipeline by Arno Therapeutics, Inc., H1 2016
  • Neurofibromatoses Type II - Pipeline by CalAsia Pharmaceuticals, Inc., H1 2016
  • Neurofibromatoses Type II - Pipeline by Lixte Biotechnology Holdings, Inc., H1 2016
  • Neurofibromatoses Type II - Pipeline by Novartis AG, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Neurofibromatoses Type II Therapeutics - Recent Pipeline Updates, H1 2016
  • Neurofibromatoses Type II - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Neurofibromatoses Type II, H1 2016
  • Number of Products under Development for Neurofibromatoses Type II - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top